A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs AB 122 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 09 May 2018 According to an Arcus Biosciences media release, dosing initiated in a third cohort and company expect to present safety, pharmacokinetic, receptor occupancy and clinical activity data in the second half of 2018.
- 20 Nov 2017 New trial record
- 13 Nov 2017 According to an Arcus Biosciences media release, the company initiated this trial in November and data is anticipated in 2018.